Lactobacillus plantarum capable of relaxing bowels and application of lactobacillus plantarum

Abstract

The invention discloses lactobacillus plantarum ZSHT-001 capable of relaxing bowels and application of the lactobacillus plantarum ZSHT-001, and belongs to the technical field of biology, and the lactobacillus plantarum ZSHT-001 is separated from pickled vegetables. The preservation number of the lactobacillus plantarum is GDMCC No: 66147. A fermentation product of the lactobacillus plantarum ZSHT-001 provided by the invention has excellent antibacterial performance, good acid resistance and cholate resistance and relatively high gastrointestinal tract peristalsis promoting capacity, has the potential of relieving constipation, and has important significance in developing medicines, health-care products and foods for preventing or treating constipation.

Description

Technical Field

[0001] The invention relates to the field of biotechnology, and in particular to a strain of Lactobacillus plantarum capable of moistening the intestine and promoting bowel movements and an application thereof. Technical Background

[0002] Constipation has become a common digestive tract dysfunction problem in modern society. Symptoms such as abdominal distension and pain caused by difficulty in defecation and hard stools significantly affect the quality of life of patients. Long-term constipation not only leads to the accumulation of toxins in the intestine and bacterial flora disorders, but may also induce organic lesions such as hemorrhoids and intestinal obstruction, forming a vicious cycle. Although chemical laxatives commonly used in clinical practice can quickly relieve symptoms, long-term use can easily lead to drug dependence problems such as electrolyte imbalance and decreased intestinal nerve sensitivity. Traditional dietary fiber supplements have limitations such as a long onset period and significant individual response differences, making it difficult to meet patients' needs for safe and effective therapies.

[0003] Probiotic therapy has attracted attention as an alternative intervention method. Its mechanism of action by regulating intestinal flora to promote metabolism has the advantage of natural safety. However, the functional performance of conventional Lactobacillus plantarum strains in promoting intestinal motility and stimulating intestinal nerve activity is uneven, and the content of functional components such as short-chain fatty acids and bioactive peptides in the metabolites of most strains is insufficient, which cannot effectively synergize to improve intestinal motility and inhibit the excessive proliferation of pathogenic bacteria. What is more noteworthy is that the current probiotic fermentation process generally uses standardized culture medium and lacks precise regulation of constipation-related metabolic pathways, resulting in a single type of organic acid produced by the strain, making it difficult to break through the technical bottleneck of traditional probiotic preparations that are slow to take effect and have no significant effect. Based on the above problems, screening a specific strain with the effect of relieving constipation and its adaptive culture system has become an important direction for solving the problem of constipation intervention. Summary of the Invention

[0004] The present invention aims to provide a strain of Lactobacillus plantarum that can moisten the intestines and promote bowel movements, and its application. The fermentation product obtained by using the Lactobacillus plantarum as a fermentation strain has excellent antibacterial properties, good acid and bile salt resistance, and a high ability to promote gastrointestinal motility, and has the potential to relieve constipation.

[0005] The present invention isolated and screened a strain ZSHT-001 from kimchi. Through biochemical property analysis and 16S rRNA gene comparison, the strain was identified as Lactobacillus plantarum and named Lactobacillus plantarum ZSHT-001. The Lactobacillus plantarum was deposited with the Guangdong Provincial Microbiological Culture Collection on April 14, 2025, with the deposit number GDMCC No: 66147.

[0006] In vitro experiments have shown that the fermentation product obtained by using the plant lactobacillus as the fermentation strain can significantly inhibit harmful intestinal flora and has the effect of relieving constipation.

[0007] Preferably, the preparation of the fermentation product comprises the following steps:

[0008] Step 1: Dilute the activated ZSHT-001 bacterial suspension with sterile water to 1*10 7 -1*10 8 CFU / mL of bacterial culture solution;

[0009] Step 2: Inoculate the bacterial seed liquid into the liquid culture medium at an inoculum rate of 1-3 v / v%, ferment and culture for 24-36 hours, and filter to obtain the fermentation product filtrate;

[0010] Step 3: freeze-drying the fermentation product filtrate to obtain the fermentation product.

[0011] Preferably, the liquid culture medium is MRS liquid culture medium;

[0012] Furthermore, the liquid culture medium is a specific liquid culture medium, and the specific liquid culture medium comprises the following raw materials in parts by weight:

[0013] 3-6 parts of okra extract;

[0014] 3-5 portions of wheat peptide;

[0015] 2-4 parts inulin;

[0016] 4-6 parts of oligofructose;

[0017] 1-3 parts polydextrose;

[0018] 2-4 parts of arabinose;

[0019] 40-50 parts of sterile deionized water.

[0020] The second object of the present invention is to provide the use of Lactobacillus plantarum ZSHT-001 in the preparation of food or health products with the effect of relieving constipation.

[0021] The third object of the present invention is to provide the use of Lactobacillus plantarum ZSHT-001 in the preparation of food or health products having the effect of regulating intestinal flora.

[0022] Beneficial effects of the present invention:

[0023] The present invention provides a Lactobacillus plantarum strain ZSHT-001, which has a deposit number of GDMCC No. 66147. A fermentation product obtained by fermenting the strain ZSHT-001 using an MRS culture medium or a culture medium prepared using okra extract, wheat peptide, inulin, oligofructose, polydextrose, and arabinose as raw materials as a substrate has good constipation relief effect and can significantly inhibit the reproduction of gastrointestinal pathogens, especially having a good inhibitory effect on Escherichia coli, Staphylococcus aureus, Salmonella typhimurium, and Listeria monocytogenes. The fermentation product can be used to prepare a product for preventing or improving constipation.

[0024] Biomaterial Deposit

[0025] A strain of Lactobacillus plantarum ZSHT-001, classified and named Lactiplantibacillus plantarum, was deposited in the Guangdong Provincial Microbiological Culture Collection Center on April 14, 2025, with the deposit number GDMCC No: 66147, and the deposit address is 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou. DETAILED DESCRIPTION

[0026] The present invention will be further described below with reference to specific embodiments. It should be noted that the description of these embodiments is intended to aid understanding of the present invention and does not constitute a limitation of the present invention. In addition, the technical features involved in the various embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.

[0027] The sources of purchase of some raw materials for the present invention are as follows:

[0028] Okra extract: purchased from Zhongbai Xingye Food Technology (Beijing) Co., Ltd.

[0029] Wheat peptide: purchased from Zhejiang Pingtairong Biotechnology Co., Ltd.;

[0030] Inulin: purchased from Zhongbai Xingye Food Technology (Beijing) Co., Ltd.

[0031] Fructooligosaccharide: purchased from Quantum Hi-Tech (Guangdong) Biological Co., Ltd.

[0032] Polydextrose: purchased from Shandong Bailong Chuangyuan Biotechnology Co., Ltd.

[0033] Arabinose: purchased from Zhejiang Huakang Pharmaceutical Co., Ltd.

[0034] The remaining raw materials are commercially available unless otherwise specified.

[0035] Example 1 Isolation, screening and identification of strains

[0036] 1. Discovery and Isolation of Strain

[0037] Materials: Kimchi was purchased from Shandong Nongyu Food Co., Ltd. 5 g of kimchi leaves were placed in 10 mL of sterile saline and homogenized to obtain kimchi homogenate.

[0038] Take 5mL kimchi homogenate and add it into 45mL sterile saline, shake well, and then dilute it to 10mL with normal saline. -5 , 10 -6 , 10 -7 , respectively, spread on MRS solid medium, with 3 replicates for each gradient. Place the coated plates in an incubator and culture at 37°C for 1 day. Select colonies with obvious differences and streak them on MRS solid medium, culture them at 37°C for 1 day, repeat the streak 3 times, and pick a single colony for hydrogen peroxide titration. If the selected single colony produces bubbles on a slide with 5% hydrogen peroxide solution, it is a positive catalase test. If no bubbles are produced, it is a negative catalase test. Strains with negative tests are suspected to be probiotic strains. Six suspected probiotic strains were screened using this method.

[0039] 2. Screening of the antibacterial ability of suspected probiotic strains against Listeria monocytogenes and Salmonella typhimurium

[0040] Experimental method: The 6 suspected probiotic strains obtained by screening were marked as 1-6. Strains 1-6 were cultured in MRS liquid medium at 37℃ for 1 day to obtain bacterial solution, and the bacterial solution was diluted to 10 8 CFU / mL was used to obtain a bacterial suspension, and the inhibitory rate of the bacterial suspension against Listeria monocytogenes and Salmonella typhimurium was determined using the filter paper method (three replicates were performed for each strain 1-6). The amount of bacterial suspension used was 100 μL.

[0041] Preparation of culture dish for inhibited bacteria: prepare the inhibited bacteria into 10 8 CFU / mL, draw 1mL and add it to the sterilized MRS solid culture medium, spread it evenly, and obtain the culture dish with inhibited bacteria.

[0042] 3. Screening of the tolerance of suspected probiotic strains to artificial gastric juice and bile salts

[0043] Preparation of artificial gastric juice: prepare 0.5 wt % sodium chloride solution, add 0.3 wt % pepsin, and after fully dissolving, adjust the pH to 1.5 with 1 mol / L HCl, filter and sterilize with a 0.22 μm microporous filter membrane for later use.

[0044] Preparation of bile salts: Add bile salts to MRS liquid culture medium to prepare MRS culture medium containing 0.6% bile salts. After fully dissolving, filter and sterilize with a 0.22 μm microporous filter membrane for later use.

[0045] Experimental method: The labeled strains 1-6 were cultured in MRS liquid medium at 37°C for 1 day to obtain bacterial solution, and sterile deionized water was used to dilute the bacterial solution to 10 8 CFU / mL to obtain a bacterial suspension, and add 0.5 mL of the bacterial suspension to 4.5 mL of the prepared artificial gastric juice or bile salt solution and mix well to obtain a 1 v / v% bacterial artificial gastric juice or bile salt solution. The bacterial artificial gastric juice or bile salt solution was incubated at 37°C, and the digestive fluid was collected at 0 h and 3 h to detect the number of viable bacteria. The survival rate of the strain in artificial gastric juice and bile salt solution was calculated according to the strain survival rate formula (three replicates were performed for each strain 1-6);

[0046] Strain survival rate = (N1 / N0)*100%

[0047] N1 represents the number of viable bacteria after 3 h of treatment, and N0 represents the number of viable bacteria at 0 h.

[0048] The results of the antibacterial ability of the suspected probiotic strains are shown in Table 1 below.

[0049] Table 1 Antibacterial ability, acid resistance and bile salt resistance of suspected probiotic strains

[0050]

[0051]

[0052] The results in Table 1 show that strain No. 3 has good antibacterial properties against Listeria monocytogenes and Salmonella typhimurium, and strain No. 3 has good tolerance to artificial gastric juice and bile salts, so strain No. 3 was selected as the optimal strain.

[0053] Morphological identification of strains

[0054] Strain No. 3 was morphologically identified as a Gram-positive bacterium, with white colonies, smooth protrusions, straight rods in short chains, no spores, no flagella, homotypic fermentation, no gas production when fermenting glucose, no nitrite reduction, no indole production, negative hydrogen sulfide production, and coagulase negative; the strain was rod-shaped under an ordinary microscope.

[0055] Molecular biological identification of strains

[0056] The strain, numbered 3, obtained through screening, was identified using molecular biological methods. Sequencing revealed the 16sRNA sequence of the strain as shown in SEQ ID NO. 1. BLAST comparison of the sequencing results with the NCBI database and phylogenetic tree construction revealed that the strain sequence was highly homologous to the gene sequence of Lactiplantibacillus plantarum, with a homology of 100%. Combined with its morphological characteristics, the strain was identified as belonging to Lactiplantibacillus plantarum.

[0057] The strain was named Lactobacillus plantarum ZSHT-001, with the scientific name Lactiplantibacillus plantarum, and was deposited in the Guangdong Provincial Microbial Culture Collection Center on April 14, 2025, with the address at 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, China, with a postal code of 510070, and the deposit number is GDMCC No: 66147.

[0058] Application Example: Preparation of Fermentation Products

[0059] A fermentation product for preventing or improving constipation, the preparation method of which comprises the following steps:

[0060] Application Example 1:

[0061] Step 1: Dilute the activated ZSHT-001 bacterial suspension with sterile water to 1×10 7 CFU / mL of bacterial culture solution;

[0062] Step 2: inoculating the bacterial seed liquid into MRS liquid culture medium at an inoculum rate of 2 v / v%, fermenting for 30 hours, and filtering to obtain a fermentation product filtrate;

[0063] Step 3: freeze-drying the fermentation product filtrate to obtain the fermentation product.

[0064] Application Example 2:

[0065] Step 1: Dilute the activated ZSHT-001 bacterial suspension with sterile water to 1×10 7 CFU / mL of bacterial culture solution;

[0066] Step 2: inoculating the bacterial seed liquid into a specific liquid culture medium at an inoculum rate of 2 v / v%, fermenting and culturing for 30 hours, and filtering to obtain a fermentation product filtrate;

[0067] Step 3: freeze-drying the fermentation product filtrate to obtain a fermentation product;

[0068] The specific liquid culture medium in step 2 includes the following raw materials in parts by weight:

[0069] 5 parts of okra extract;

[0070] 4 portions of wheat peptide;

[0071] 3 parts inulin;

[0072] 5 parts of oligofructose;

[0073] 2 parts polydextrose;

[0074] 3 parts of arabinose;

[0075] 45 parts of sterile deionized water.

[0076] Application Example 3:

[0077] Different from Application Example 2, the specific liquid culture medium in step 2 includes the following raw materials in parts by weight:

[0078] 3 parts of okra extract;

[0079] 5 portions of wheat peptide;

[0080] 2 parts inulin;

[0081] 6 parts of oligofructose;

[0082] 1 part polydextrose;

[0083] 2 parts of arabinose;

[0084] 40 parts of sterile deionized water.

[0085] Application Example 4:

[0086] Different from Application Example 2, the specific liquid culture medium in step 2 includes the following raw materials in parts by weight:

[0087] 6 parts of okra extract;

[0088] 3 parts of wheat peptide;

[0089] 4 parts of inulin;

[0090] 4 parts of oligofructose;

[0091] 3 parts polydextrose;

[0092] 4 parts of arabinose;

[0093] 50 parts of sterile deionized water.

[0094] Comparative application example 1:

[0095] The difference from Application Example 1 is that Lactobacillus plantarum ZJUF SYS1 is used instead of Lactobacillus plantarum ZSHT-001. The preservation number of Lactobacillus plantarum is: CCTCC NO: M2022662. The other parameters and steps are the same as those in Application Example 2.

[0096] Comparative application example 2:

[0097] The difference from Application Example 1 is that Lactobacillus plantarum La-10 is used instead of Lactobacillus plantarum ZSHT-001. The preservation number of Lactobacillus plantarum is GDMCC NO: 63605. The other parameters and steps are the same as those in Application Example 2.

[0098] Comparative application example 3:

[0099] Different from Application Example 2, the specific liquid culture medium does not contain wheat peptide, and the missing mass parts are made up with okra extract, inulin, oligofructose, polydextrose, arabinose, and sterile deionized water in a mass ratio of 5:3:5:2:3:45. The remaining parameters and steps are the same as those in Application Example 2.

[0100] Comparative application example 4:

[0101] Different from Application Example 2, the specific liquid culture medium does not contain okra extract, and the missing mass parts are supplemented by wheat peptide, inulin, oligofructose, polydextrose, arabinose and sterile deionized water in a mass ratio of 4:3:5:2:3:45. The remaining parameters and steps are the same as those in Application Example 2.

[0102] Efficacy verification:

[0103] 1) Efficacy verification of Lactobacillus plantarum fermentation products on constipation model mice

[0104] Preparation of test samples: Prepare a 15 wt % mixed solution of Application Examples 1-4 and Comparative Application Examples 1-4 using sterile deionized water, and seal the mixture for use.

[0105] 200 SPF male Kunming mice weighing 20±2g were selected and the mice were adaptively raised for one week. During the raising period, they were allowed to eat and drink freely.

[0106] After one week of feeding, 100 mice were randomly selected as experimental animals, weighing 18-22 g. The experimental animals were randomly divided into 10 groups, each with 10 mice, namely a blank group, a model control group, an application example 1-4 group, and a comparative application example 1-4 group. Except for the blank group, the remaining groups were gavaged with loperamide hydrochloride (5 mg / kg bw) every day, once in the morning and once in the evening, for 7 consecutive days to induce a functional constipation model in mice. The blank group was gavaged with an equal amount of normal saline every day. Then, the test samples (application example 1-4 group, comparative application example 1-4 group) were taken and gavaged into the experimental group every day, with a gavage volume of 0.2 mL / 10 g body weight. During this period, the blank group and the model group were gavaged with an equal amount of normal saline. During the experiment, all mice were allowed to eat and drink freely for 14 consecutive days. After the end of the 14th day, the mice in each group were fasted for 12 hours but not water. Then, each group was gavaged for the last time. One hour after gavage, each group was gavaged with 0.1 mL / 10 g body weight of activated carbon suspension. Twenty minutes after the end of gavage, the mice were killed by cervical dislocation, and the small intestine was removed by laparotomy. The carbon powder propulsion distance and the total length of the small intestine were measured, and the propulsion rate (%) was calculated. The experimental results are the average value with two decimal places, as shown in Table 1.

[0107] The activated carbon suspension was prepared by using deionized water and gum arabic to prepare a 5 (w / v)% activated carbon suspension from activated carbon powder.

[0108] Advancement rate (%) = carbon powder advancement distance / total length of small intestine * 100%.

[0109] The higher the propulsion rate, the better the effect of relieving constipation.

[0110] Table 2 Verification of constipation relief efficacy

[0111] Group Advancement rate / % Blank group 70.36％±4.14* Model control group 36.54％±2.49 Application Example 1 63.43％±3.25* Application Example 2 74.37％±2.32* Application Example 3 70.62％±4.17* Application Example 4 72.31％±3.45* Comparative Application Example 1 50.51％±6.31* Comparative Application Example 2 47.34％±4.36* Comparative Application Example 3 65.36％±5.49* Comparative Application Example 4 67.93％±3.27*

[0112] Note: “*” indicates p < 0.05 compared with the model control group.

[0113] As shown in Table 1, the small intestinal propulsion rate of the model control group was significantly reduced compared with the blank group, indicating that the constipation model was successfully established.

[0114] Comparison of the results of Application Example 1 with those of the model control group shows that the Lactobacillus plantarum ZSHT-001 provided by the present invention has a certain effect in alleviating constipation.

[0115] Comparison of the results of Application Examples 1-2 shows that the fermentation product obtained by fermenting the Lactobacillus plantarum ZSHT-001 provided by the present invention using the special culture medium defined in the present invention has a better effect in alleviating constipation.

[0116] Comparison of the results of Application Example 1 and Comparative Application Examples 1-2 shows that, compared with other Lactobacillus plantarum with similar efficacy, the Lactobacillus plantarum ZSHT-001 provided by the present invention has a better effect in alleviating constipation.

[0117] Comparison of the results of Application Example 2 with those of Comparative Application Examples 3-4 shows that changes in the culture medium components have a certain impact on the small intestinal propulsion rate, and the fermentation product cultured using the special culture medium defined in the present invention has a better effect in alleviating constipation.

[0118] 2) Verification of the inhibitory efficacy of Lactobacillus plantarum ZSHT-001 fermentation products against Escherichia coli and Staphylococcus aureus

[0119] Preparation of test samples: Prepare a 15 wt% mixed solution using sterile deionized water from Application Example 1-2 and Comparative Application Example 1-2, and seal the solution for later use.

[0120] Experimental method: The antibacterial ability of different harmful bacteria was determined by using the filter paper method. Escherichia coli and Staphylococcus aureus were inoculated into LB liquid culture medium, cultured on a shaking table at 37℃ for 24h, and then the bacterial solution was diluted to 10 8 CFU / mL. 0.1 mL of the diluted bacterial solution was evenly spread on a nutrient agar plate. Two sterile 5 mm diameter filter paper slips were then placed on the spread agar plate. 10 μL of the test sample was added to the filter paper slips for the experimental group, while an equal amount of sterile deionized water was added to the control group. The cells were incubated at 37°C for 24 h and the diameter of the inhibition zone was measured. The experiment was repeated three times, and the results are presented as mean ± standard deviation, as shown in Table 2.

[0121] Table 3 Antibacterial test of Lactobacillus plantarum ZSHT-001 fermentation products

[0122]

[0123] The results showed that Lactobacillus plantarum ZSHT-001 had a strong inhibitory ability against two common pathogens, Escherichia coli and Staphylococcus aureus, with the best effect against Escherichia coli and the second best against Staphylococcus aureus.

[0124] Acute toxicity test:

[0125] Conduct acute toxicity tests on test samples to verify their safety.

[0126] Test samples: Application examples 1-4;

[0127] Experimental methods:

[0128] Forty SPF-grade Kunming mice weighing 20 ± 2 g (half male and half female) were selected. 20 g of the test sample was diluted to 60 mL with purified water to achieve the maximum permissible gavage concentration. The mice were orally gavaged twice daily, 6 hours apart, with a volume of 0.3 mL / 10 g body weight per gavage, equivalent to a dose of 20.00 g / kg body weight. The mice were fasted for 6 hours before the first gavage. Following gavage, they were observed for two weeks, and any signs of poisoning and mortality were recorded.

[0129] Experimental results: Kunming mice showed no obvious symptoms of poisoning after oral administration, and no deaths occurred during the 14-day observation period. At the end of the observation period, the animals were sacrificed and autopsied, revealing no significant abnormalities in major organs, including the liver, spleen, kidneys, intestines, heart, and lungs. The fermentation product of this invention demonstrated a median lethal dose (LD50) of greater than 20.00 g / kg·bw for Kunming mice. According to the acute toxicity dose grading standard in GB 15193.3-2014, it is classified as practically non-toxic.

[0130] A health product for preventing or improving constipation, the preparation method of which comprises the following steps:

[0131] Health supplement 1:

[0132] The fermentation product prepared in Application Example 1 was prepared into a 15 wt% mixed solution using drinking water, and then 1 wt% white sugar and 0.05 wt% vitamin C were added, mixed evenly, filled, and sealed for storage.

[0133] Health supplement 2:

[0134] The fermentation product prepared in Application Example 2 was prepared into a 15 wt% mixed solution using drinking water, and then 1 wt% white sugar and 0.05 wt% vitamin C were added, mixed evenly, filled, and sealed for storage.

[0135] Health supplement 3:

[0136] The fermentation product prepared in Application Example 3 was prepared into a 15 wt% mixed solution using drinking water, and then 1 wt% white sugar and 0.05 wt% vitamin C were added, mixed evenly, filled, and sealed for storage.

[0137] Health Products 4:

[0138] The fermentation product prepared in Application Example 4 was prepared into a 15 wt% mixed solution using drinking water, and then 1 wt% white sugar and 0.05 wt% vitamin C were added, mixed evenly, filled, and sealed for storage.

[0139] The embodiments of the present invention are described in detail above, but the present invention is not limited to the described embodiments. It is apparent to those skilled in the art that various changes, modifications, substitutions, and variations to these embodiments may be made without departing from the principles and spirit of the present invention, and the changes still fall within the scope of protection of the present invention.

Claims

1. A strain of Lactobacillus plantarum ZSHT-001, characterized in that: The Lactobacillus plantarum ZSHT-001 was deposited in the Guangdong Provincial Microbial Culture Collection Center on April 14, 2025, with the deposit number: GDMCC No: 66147.

2. A bacterial agent, characterized in that Including the Lactobacillus plantarum ZSHT-001 according to claim 1.

3. A fermentation product comprising the Lactobacillus plantarum ZSHT-001 according to claim 1 or the bacterial agent according to claim 2.

4. The fermentation product according to claim 3, characterized in that The method for preparing the fermentation product comprises the following steps: Step 1: Dilute the activated ZSHT-001 bacterial suspension with sterile water to 1*10 7 -1*10 8 CFU / mL of bacterial culture solution; Step 2: Inoculate the bacterial seed liquid into the liquid culture medium at an inoculum rate of 1-3 v / v%, ferment and culture for 24-36 hours, and filter to obtain the fermentation product filtrate; Step 3: freeze-drying the fermentation product filtrate to obtain a fermentation product; The liquid culture medium in step 2 is MRS liquid culture medium or specific liquid culture medium; The specific liquid culture medium in step 2 includes the following raw materials in parts by weight: 3-6 parts of okra extract; 3-5 portions of wheat peptide; 2-4 parts inulin; 4-6 parts of oligofructose; 1-3 parts polydextrose; 2-4 parts of arabinose; 40-50 parts of sterile deionized water.

5. Use of the Lactobacillus plantarum ZSHT-001 according to claim 1, the bacterial agent according to claim 2, or the fermentation product according to claim 3 or 4 in the preparation of a product for preventing or improving constipation.

6. The application according to claim 5, characterized in that The product is a food or a health product.

7. A health product that helps to moisten the intestines and promote bowel movements, characterized in that: The method comprises at least one of the Lactobacillus plantarum ZSHT-001 according to claim 1, the bacterial agent according to claim 2, or the fermentation product according to claim 3 or 4.

8. Use of the Lactobacillus plantarum ZSHT-001 according to claim 1, the bacterial agent according to claim 2, or the fermentation product according to claim 3 or 4 in the preparation of a health product that helps regulate intestinal flora.

9. A health product that helps regulate intestinal flora, characterized in that: The method comprises at least one of the Lactobacillus plantarum ZSHT-001 according to claim 1, the bacterial agent according to claim 2, or the fermentation product according to claim 3 or 4.

10. The health care product according to claim 7 or 9, characterized in that: Also included are food-acceptable excipients.

Images